Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) EBITDA (2016 - 2025)

Angiodynamics (ANGO) has disclosed EBITDA for 16 consecutive years, with -$6.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 44.79% year-over-year to -$6.1 million, compared with a TTM value of -$32.5 million through Nov 2025, up 86.36%, and an annual FY2025 reading of -$40.0 million, up 79.24% over the prior year.
  • EBITDA was -$6.1 million for Q4 2025 at Angiodynamics, up from -$10.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $35.0 million in Q3 2023 and bottomed at -$199.9 million in Q1 2024.
  • Average EBITDA over 5 years is -$17.7 million, with a median of -$9.5 million recorded in 2023.
  • The sharpest move saw EBITDA soared 363.36% in 2023, then crashed 2138.98% in 2024.
  • Year by year, EBITDA stood at -$8.7 million in 2021, then increased by 6.5% to -$8.1 million in 2022, then crashed by 61.68% to -$13.1 million in 2023, then rose by 15.44% to -$11.1 million in 2024, then skyrocketed by 44.79% to -$6.1 million in 2025.
  • Business Quant data shows EBITDA for ANGO at -$6.1 million in Q4 2025, -$10.7 million in Q3 2025, and -$5.8 million in Q2 2025.